Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Paolo Provenzano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9313-1370; OpenAlex author ID A5070953226, A5160284263; NIH RePORTER profile ID 8646666. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 7)
Trials
0
Grants
6
Labs led
2
Collaborators
43
Papers, trials and grants by year

2011: 1 grant · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper, 1 grant · 2019: 2 papers · 2020: 1 paper, 1 grant · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers, 1 grant · 2026: 2 papers, 2 grants

Papers 14

  1. Decoding spatiotemporal fibrotic and cellular immunosuppression of therapeutic T cells in live pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s44320-026-00243-4↗
  2. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2026-015489↗
  3. Computationally Enabled Polychromatic Polarized Imaging Enables Mapping of Matrix Architectures that Promote Pancreatic Ductal Adenocarcinoma Dissemination. Last author DOI 10.1016/j.ajpath.2025.04.017↗
  4. Extracellular matrix architecture promotes immunosuppressive microenvironments in pancreatic cancer. Last author DOI 10.1016/j.matbio.2025.09.004↗
  5. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
  6. Protocol to culture and image pancreatic ductal adenocarcinoma tumor slices to study T cell migration. Last author DOI 10.1016/j.xpro.2023.102135↗
  7. Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci.insight.150330↗
  8. Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. Last author DOI 10.1172/jci.insight.153242↗
  9. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis. Co-author DOI 10.1053/j.gastro.2020.07.046↗
  10. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-18-1334↗
  11. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060772↗
  12. Physical and Chemical Enhancement of and Adaptive Resistance to Irreversible Electroporation of Pancreatic Cancer. Co-author DOI 10.1007/s10439-017-1932-3↗
  13. Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. Co-author DOI 10.1016/j.bpj.2016.03.040↗
  14. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2012.01.007↗

Grants 6

  1. Stomal Senescence Regulator of Tumor Immunity and Progression R01CA286615↗
  2. Research Testbed 1 U54CA268069↗
  3. Project 1 P01CA254849↗
  4. Project 1: Physical modeling and dynamics of tumor cell migration mechanics U54CA210190↗
  5. Stellate cells and their progenitor precursors in pancreas cancer progression R01CA181385↗
  6. Dissecting the roles of stellate cells in pancreas cancer progression R21CA152249↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 2 shared papers, 1 shared grant, 2022–2026 · strength 1.57
  2. David J. Odde · 2 shared grants, 2020–2025 · strength 1.21
  3. Guhan Qian · 4 shared papers, 2024–2026 · strength 1.09
  4. David Masopust · 1 shared paper, 1 shared grant, 2025–2026 · strength 0.96
  5. Mackenzie Kate Callaway · 3 shared papers, 2022–2025 · strength 0.81
  6. David Andrew Largaespada · 1 shared grant, 2025 · strength 0.73
  7. Kevin W. Eliceiri · 2 shared papers, 2025–2026 · strength 0.69
  8. Ingunn M. Stromnes · 2 shared papers, 2026 · strength 0.61
  9. Sunil R. Hingorani · 4 shared papers, 1 shared grant, 2011–2026 · strength 0.53
  10. Nelson J. Rodríguez-Merced · 2 shared papers, 2022–2023 · strength 0.44
  11. Ajay Kumar Dixit · 2 shared papers, 2020–2022 · strength 0.26
  12. Kianna Y. Elahi-Gedwillo · 2 shared papers, 2018–2019 · strength 0.23
  13. Adam L. Burrack · 1 shared paper, 2026 · strength 0.23
  14. Zoe C. Schmiechen · 1 shared paper, 2026 · strength 0.23
  15. Grant H. Hickok · 1 shared paper, 2026 · strength 0.23
  16. Alexander K. Tsai · 1 shared paper, 2026 · strength 0.23
  17. Philip D. Greenberg · 1 shared paper, 2026 · strength 0.23
  18. Huocong Huang · 1 shared paper, 2022 · strength 0.17
  19. Rolf A. Brekken · 1 shared paper, 2022 · strength 0.17
  20. Varintra E. Lander · 1 shared paper, 2024 · strength 0.17
  21. John M. Baer · 1 shared paper, 2024 · strength 0.17
  22. Blake E. Sells · 1 shared paper, 2024 · strength 0.17
  23. Liang‐I Kang · 1 shared paper, 2024 · strength 0.17
  24. Jad I. Belle · 1 shared paper, 2024 · strength 0.17
  25. Hyun Jee Kim · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.